Diginex (DGNX) – The ESG Tech Stock Soaring in 2025: What Investors Need to Know

• Stock Price (Oct 2025): ~$16.50 per share (52-week range: $0.45 – $19.54) ^[1]. The stock has skyrocketed from penny-stock levels to new highs, a meteoric rise of over +3,000% within 2025.
• Market Cap: Approximately $3 billion as of Q4 2025 ^[2], making Diginex a multi-billion dollar company despite its recent IPO.
• Sector & Industry: Diginex is not a traditional biotech – it’s a Sustainability RegTech company (ESG-focused SaaS). It provides software for ESG (Environmental, Social, Governance) data reporting and supply chain compliance ^[3]. (For context, we’ll compare it to biotech peers due to similar early-stage profiles.)
• 2025 Financials: Tiny revenues, growing fast. Fiscal 2025 revenue was $2.04 million (up ~57% from $1.30M in 2024) ^[4], while net loss widened slightly to -$5.21 million ^[5]. This reflects heavy investment and growth focus over profitability.
• Valuation: Sky-high multiples. At ~$3B market value and negligible sales, DGNX trades at an astronomical ~1,424× trailing sales ^[6] (Price/Sales) – a valuation far above typical biotech or software peers. The stock’s book value is also minimal (P/B >600×) ^[7]. Investors are clearly pricing in massive future growth.
• Stock Momentum 2025: Year-to-date, DGNX is one of the top-performing small-caps, climbing from under $1 (post-split basis) to nearly $20 ^[8]. Volatility is high – the share price has overshot both its 50-day ($9.64) and 200-day ($10.26) moving averages after recent news ^[9]. Early investors have seen huge gains, but recent buyers face a wild ride.

What Does Diginex Do? – Company Profile

Diginex Limited (NASDAQ: DGNX) is a London-headquartered “sustainable fintech” firm offering cloud-based software to help organizations manage ESG reporting, climate disclosures, and supply-chain due diligence ^{[10] [11]}. Its flagship platform diginexESG allows companies to collect and publish sustainability data in line with global frameworks (GRI, SASB, TCFD, etc.) ^{[12] [13]}. Other products like diginexLUMEN address supply chain risk, and diginexAPPRISE aids ESG benchmarking ^{[14] [15]}.

In essence, Diginex is positioning itself as a “one-stop-shop” for ESG compliance tech, leveraging blockchain, AI and data analytics to increase transparency in corporate sustainability reporting ^{[16] [17]}. This niche – ESG reporting software – has strong tailwinds from rising regulatory requirements worldwide (e.g. Europe’s new climate disclosure rules) and the push for corporate accountability. Diginex’s mission resonates with these trends, which partly explains investors’ enthusiasm for the stock.

Financial and Strategic Position (2025): As a newly public company (IPO in Jan 2025), Diginex started with a modest capital raise (~$9.2M ^[18]) and just 23 employees ^[19]. Despite modest sales (~$2M) and continued losses, the company’s strategy is aggressive growth: it has been acquiring complementary businesses, forming strategic alliances, and securing high-profile investors (detailed in the next section). These moves aim to rapidly scale Diginex’s capabilities in AI, data management, and global reach – effectively “buying” growth and tech know-how with stock.

Notably, Diginex carries minimal debt (total debt ~$0.24M vs $6.2M assets after IPO) ^{[20] [21]}, and it bolstered its balance sheet through strategic deals (including potential new equity from warrants, see below). However, issuing shares for acquisitions means significant equity dilution – which Diginex has so far offset with soaring share prices. The result is a company valued in the billions that is pre-profit and pre-scale, akin to an early-stage biotech in financial profile. This high-risk, high-reward profile has drawn speculative investors and caution from analysts (as we’ll see, the stock has a consensus “Sell” rating despite its momentum).

Recent News & Developments in 2025

Diginex’s 2025 has been eventful, marked by rapid-fire corporate actions and news. Here’s a rundown of the most important developments shaping the stock this year:

• 7-for-1 Stock Split (September 2025): To improve liquidity and accessibility, Diginex’s board approved a 7-for-1 forward stock split effective September 8, 2025 ^{[22] [23]}. Shareholders of record on Sept 5 received 7 bonus shares per share held. This cut the trading price by an 8× factor (without changing market cap), making shares more affordable to small investors. The split was timed alongside major expansion news (see next point) and helped fuel a post-split rally. Insider Monkey noted DGNX as “one of the must-buy small-cap stocks” after the split announcement ^[24].
• Acquisition of Resulticks – $2 Billion Deal: In June 2025, Diginex signed an MOU to acquire Resulticks – a Singapore-based AI-driven customer engagement platform – in a blockbuster $2.0 billion transaction ^{[25] [26]}. The deal is structured mostly in stock: $1.4B worth of DGNX shares (at ~$72/share pre-split) plus $100M cash and up to $500M earn-out ^{[27] [28]}. This is a transformative move: Resulticks’ technology in real-time big-data marketing will “significantly enhance Diginex’s capabilities in advanced data management and AI”, positioning Diginex as a broader data-driven ESG solutions provider ^{[29] [30]}. Management highlighted that integrating Resulticks will turn sustainability data into a “customer engagement engine” – e.g. using ESG insights to deepen brand loyalty ^[31]. Strategic rationale: Diginex is essentially using its richly valued stock as currency to buy a growth-stage tech company, betting that AI and data personalization will differentiate its ESG platform. (As of Q4 2025, the Resulticks deal was at definitive agreement stage ^[32] but not yet closed.)
• Acquisition of Matter DK (ESG Analytics Firm): In May 2025, Diginex agreed to acquire Matter DK ApS, a Copenhagen-based ESG data analytics startup, for $13 million in an all-share deal ^{[33] [34]}. Matter specializes in sustainability data and benchmarking for the investment industry. The acquisition closed in October 2025 ^[35], strengthening Diginex’s AI-driven ESG data and analytics capabilities and adding talent from a company whose major shareholder was Nasdaq, Inc. ^[36]. Diginex’s Chairman hailed that “Matter’s expertise in ESG data complements our tech and moves us into a sector with huge growth potential” ^[37]. Strategic rationale: This bolt-on deal expands Diginex’s product suite to offer more robust ESG data insights to asset managers and financial institutions – a key customer segment as sustainable investing grows.
• Strategic Investment – Abu Dhabi Royalty Involvement: In May 2025, Sheikh Mohammed Bin Sultan Bin Hamdan Al Nahyan (Abu Dhabi royal family) acquired warrants to purchase 6.75 million Diginex shares for $300 million in a private transaction ^[38]. If fully exercised, this would inject ~$69 million cash into Diginex’s coffers and make the Sheikh a 22.7% shareholder ^[39]. This deal solidified a strategic alliance: Diginex and the Sheikh’s investment arm plan a dual listing of Diginex on the Abu Dhabi exchange (ADX) and potentially a further capital raise of up to $250M in the UAE ^[40]. Diginex touted this partnership as “a powerful testament to our shared vision” for leveraging tech in sustainable finance ^[41]. Implication: Gaining a deep-pocketed Middle Eastern stakeholder not only validates Diginex’s vision, but also opens doors in the Gulf region (which is prioritizing sustainability, e.g. UAE Net Zero 2050 goals ^[42]). It also diversifies Diginex’s access to capital for future growth.
• Index Inclusion: In June 2025, Diginex was added to the S&P Global BMI index (Broad Market Index) ^[43]. This inclusion is a key milestone, increasing the stock’s visibility and potentially forcing index-tracking funds to buy DGNX. For a newly listed small-cap, being part of a major global index is an indicator of growing stature.
• Partnerships and Contracts: Diginex has been busy on the partnership front, expanding its global reach:
  • SGS Partnership (Aug 2025): Teamed up with SGS (a world-leading testing and certification firm) to enhance supply-chain ESG due diligence solutions ^[44]. This lends credibility and access to SGS’s client network for Diginex’s tools.
  • Indonesia “iNEED” Deal (Sept 2025): Signed agreements with Indonesia’s iNEED to roll out ESG reporting solutions for rural banks ^{[45] [46]} – tapping into emerging markets’ demand for sustainability in finance.
  • Allocations Partnership (Sept 2025): Partnered with Allocations Inc. to integrate ESG into fund management platforms ^[47], aiming at the private equity/VC space.
  • These deals underscore Diginex’s strategy of global expansion via partnerships, aligning with major institutions and regional players to drive adoption of its ESG platforms.
• Momentum into AI & Cyber: Diginex’s news flow also highlighted moves into hot areas like cybersecurity and AI. For example, recent press releases touted that acquisitions and product updates will incorporate AI capabilities and even blockchain for supply chain transparency ^[48]. This narrative of being at the intersection of ESG + AI + blockchain has likely contributed to the market’s fervor for DGNX, as it touches multiple investing buzzwords.

In summary, 2025’s developments show Diginex “growing up” fast: dramatically increasing its share count (stock split + equity deals), acquiring companies many times its own size, and forging alliances from Europe to Asia and the Middle East. Each news item added fuel to the stock’s speculative fire. However, investors should also note that execution risk is rising – integrating big acquisitions and delivering promised synergies will be the next big challenge for Diginex.

Analyst Forecasts & Investor Sentiment

Despite Diginex’s exciting story and stock surge, Wall Street analysts remain cautious. Coverage is limited (as a very small IPO, DGNX isn’t widely followed by big banks), but those who rate it are skeptical of the lofty valuation:

• Consensus Rating – “Sell”: According to MarketBeat data, Diginex carries an overall “Sell” consensus ^[49]. Weiss Ratings recently reiterated a sell rating (grade E+) on DGNX stock ^[50]. One independent research firm (Wall Street Zen) did upgrade DGNX from Sell to “Hold” in June ^[51], but no analysts currently advocate buying at these levels. The lack of formal price targets (Zacks Investment notes no targets set) ^[52] reflects how unusual Diginex’s fundamentals are – traditional metrics can’t justify the price, so analysts err on the side of caution.
• Valuation Concerns: The primary reason for the bearish stance is valuation. DGNX’s >1000× P/S multiple is orders of magnitude higher than even most high-growth SaaS or biotech stocks. By comparison, many emerging tech or biotech firms trade at 5–20× sales, and the broader market is far lower. Simply put, Diginex is priced for perfection (and then some). Any hiccups in growth or integration of acquisitions could trigger a sharp correction. Analysts also point to dilution: issuing billions in stock for acquisitions means future earnings (if they materialize) are spread over many more shares, muting per-share value.
• Momentum vs. Fundamentals – Divergent Views: There’s a clear split between momentum traders who love the stock and fundamental analysts who urge caution. A recent MarketBeat article noted the paradox: DGNX jumped 8.4% in one day on heavy trading, yet “analysts maintain a consensus rating of ‘Sell’” ^{[53] [54]}. This dynamic often occurs with story stocks – the market can bid them to the moon in the short term, while fundamentals-focused observers wave warning flags.
• Bullish Commentary: On the other hand, some pundits see genuine promise in Diginex’s vision. A Seeking Alpha analysis argued that “Diginex’s acquisitions of Resulticks and Matter DK significantly enhance its AI, data management, and ESG analytics capabilities, supporting long-term revenue growth and global expansion.” It noted that despite dilution, these moves “position Diginex as a leading ESG reporting technology platform in a rapidly growing market,” with “substantial growth opportunities as ESG regulations and demand for sustainability solutions accelerate worldwide.” ^[55] This encapsulates the bull case: Diginex is grabbing a leadership spot in an emerging ESG tech sector that could be huge in coming years. If they execute well, today’s revenue could multiply manyfold.
• Notable Investor Opinions: Diginex has started appearing on radar of small-cap investors:
  • Insider Monkey named DGNX among its “must-buy small-cap stocks” earlier in the year ^[56], citing its ESG focus and momentum. (That said, the same article cautioned that “some AI stocks [may] hold greater promise” than Diginex for 100× upside ^[57], implying DGNX might not be the absolute best risk-reward in the tech arena.)
  • Institutional interest is slowly emerging: for instance, Hong Kong-based Y Intercept Ltd took a new position in Diginex in Q1 2025 (buying ~$0.57M worth of shares) ^{[58] [59]}. While small, this shows that professional investors are starting to nibble, possibly speculating that the company’s international strategy will pay off.
  • No major bank has initiated coverage yet, which is typical for a company of this size. Investors largely have to rely on company guidance and independent research for now.
• Price Targets & Forecasts: Concrete price forecasts are scarce. One algorithmic forecast sees DGNX trading in the $16–19 range through 2025 ^[60] – essentially flat from current levels (suggesting the upside is already priced in). On the flip side, should Diginex surprise to the upside (e.g. land large paying clients or close its acquisitions smoothly), bulls argue the stock could continue its upward trajectory. At this stage, however, it’s prudent to view DGNX as a highly speculative play. Even the CEO Mark Blick has emphasized long-term vision over short-term earnings, which means volatility will likely persist.

Analyst & Expert Quotes: To capture sentiment, here are a few representative quotes:

• “Based on data from MarketBeat, Diginex currently has a consensus rating of ‘Sell.’” ^[61] – MarketBeat Instant Analysis, Oct 3, 2025.
• “Despite recent stock declines and equity dilution, [Diginex’s] strategic moves position [it] as a leading ESG reporting technology platform… International partnerships and expanding product offerings provide Diginex with substantial growth opportunities as ESG regulations accelerate worldwide.” ^[62] – Seeking Alpha, Aug 2025.
• “Diginex Ltd (DGNX) is one of the must-buy small-cap stocks to invest in [now].” ^[63] – Insider Monkey, Aug 25, 2025.
• “We acknowledge the potential of DGNX to grow, [but] believe some AI stocks hold greater promise for higher returns….” ^[64] – Insider Monkey (tempering enthusiasm, suggesting Diginex is promising but not necessarily the top pick in high-tech).

In summary, expert opinion is mixed: Diginex is either seen as an over-hyped stock far ahead of its fundamentals (the bear view), or as a pioneering ESG-AI platform riding powerful industry trends (the bull view). Both can be true – the company does have exciting prospects, but the stock’s current price leaves little margin for error. New investors should be prepared for potentially sharp swings and closely watch execution of the growth plan.

How Does DGNX Compare to Peers? (Valuation, Growth, Financial Health, Momentum)

Diginex’s unique profile makes direct comparisons tricky – there are few pure-play ESG SaaS peers public yet. However, we can contrast DGNX with similar small-cap companies that, like Diginex, have high growth potential but modest current financials. Below is a comparison with two such companies: GH Research (GHRS), a biotech with a promising drug pipeline (and similarly small revenue), and Beam Therapeutics (BEAM), a mid-stage biotech known for gene-editing therapies. This will highlight how Diginex stacks up in terms of valuation, growth, financial health, and stock momentum:

<small>Notes: (*) GHRS and BEAM net losses are estimated for illustration (both prioritize R&D over earnings). () BEAM P/S ~38× calculated from ~$2.32B market cap and $60M sales. Sources as cited. </small>

Takeaways from the comparison: Diginex’s valuation is far more stretched than even high-growth biotechs like GHRS or BEAM. While all three companies are unprofitable and banking on future growth, DGNX’s price suggests near-flawless execution is expected. GH Research, for example, has zero revenue but a market cap under $1B and a strong pipeline; analysts give it buy ratings and a ~$33 target (implying +146% upside) ^{[87] [88]} based on its depression drug prospects. Diginex, by contrast, already trades at multi-billion levels with analysts largely on the sidelines or negative. In terms of financial health, all three are bolstered by adequate cash and low debt, but Diginex will likely need additional funding or significant client revenue to justify its acquisitions long-term (the others have longer cash runways from recent raises).

Regarding stock momentum, Diginex has delivered eye-popping short-term gains that dwarf the others. GHRS had a big run on clinical news, and small-cap biotech indices have rebounded ~37% off 2025 lows ^[89], but DGNX’s surge is exceptional. This highlights that Diginex’s stock is moving more on speculative narrative (ESG + AI hype) than on measured fundamental progress (GHRS moving a drug to Phase 2, BEAM advancing trials, etc.). Investors should weigh this accordingly – momentum can cut both ways.

Industry Outlook & Trends – ESG Tech and Biotech in 2025

Diginex’s Sector – ESG/Sustainability Tech: The industry Diginex operates in can be described as ESG reporting software and sustainability data analytics. This is a rapidly growing niche in 2025. Key drivers include:

• Regulatory Tailwinds: Governments and regulators worldwide are implementing stricter ESG disclosure requirements. For instance, the EU’s Corporate Sustainability Reporting Directive (CSRD) is coming into effect, mandating thousands of companies to report on sustainability metrics. Similar moves by the SEC in the U.S. and other jurisdictions mean more firms need tools to gather and report ESG data. Diginex is targeting this need by supporting 17 global reporting frameworks in its platform ^[90].
• Corporate & Investor Demand: Beyond compliance, companies are facing pressure from investors, customers, and asset managers to improve ESG performance. Tools that help track carbon footprints, diversity metrics, or supply-chain ethics are in high demand. Diginex’s partnerships (e.g. with a banking association in Indonesia, or fund managers via Allocations Inc.) reflect the broad market for ESG tech – spanning finance, supply chains, and enterprise reporting.
• Technology Convergence: ESG tech is increasingly blending with AI, big data, and blockchain. Diginex is at this intersection – using blockchain for tamper-proof reporting and AI for analytics. The acquisition of Resulticks shows a trend of ESG platforms merging with customer engagement and big data solutions, suggesting that in the future, sustainability data will be as integral as financial data in business intelligence. The industry is moving toward real-time ESG insights (as Resulticks’ CEO put it, “ESG is no longer just about compliance; it’s a competitive lever” ^[91]).
• Competitive Landscape: The ESG software space, while new, is getting crowded. Established players like Workiva (which offers SEC and ESG reporting software) and big consultancies (Deloitte, S&P Global’s ESG services, etc.) are competing for market share. Many privately-held startups (in carbon accounting, ESG ratings, etc.) are also vying for clients. Diginex, as a first-mover via public markets, enjoys the ability to raise capital and acquire others quickly (as we’ve seen), but it will need to execute well to fend off larger entrants. The inclusion of Diginex in a global index ^[92] hints it’s being recognized, but it also now has a target on its back.
• Challenges: A major challenge for ESG tech firms is monetization and measurable ROI. Companies know they need ESG tools, but budgets can be tight if the benefits are seen as mostly compliance-related. Diginex’s strategy to tie ESG data to value-add insights (customer engagement, risk management) is one way to justify spending. Another challenge is the political backlash against “ESG” in some regions – for example, certain U.S. states pushing anti-ESG investing agendas. While the global trend is favorable, ESG has become a bit of a buzzword with mixed perceptions. Firms like Diginex must prove that their solutions drive efficiency and trust, not just satisfy regulators.

Overall, the outlook for the sustainability tech sector is robust – Deloitte projects significant growth as ESG reporting becomes standard business practice. Diginex, by aggressively expanding its product suite and global reach, aims to surf this wave. But as a pioneer, it must educate the market and deliver tangible results to stay ahead.

Biotechnology Industry Outlook (2025): Since many Diginex investors are generally interested in biotech (given the risk-reward profile), it’s worth noting the broader biotech sector trends for context:

• Recovery and Investor Sentiment: After a tough 2022–2023, the biotech sector showed signs of recovery in 2025. Small-cap biotech stocks (as measured by the XBI ETF) rallied by ~37% from April 2025 lows through mid-year ^[93], outperforming the broader S&P 500. This rebound has been fueled by hopes of interest rate cuts – historically, lower rates benefit biotech valuations by reducing the discount on future drug profits ^[94]. By late 2025, investors are tip-toeing back into riskier biotech names, especially as some big pharma companies look to partner with or acquire innovative biotechs.
• Innovation Pipeline: The industry is buzzing with new technologies – gene editing (CRISPR therapies), mRNA advancements post-COVID, cell therapies for cancer, and AI-driven drug discovery are key trends ^{[95] [96]}. Companies like Beam Therapeutics (gene editing) and others in gene therapy are at the forefront of potentially curative treatments. This innovation keeps long-term optimism alive. For example, GH Research’s novel inhalable depression treatment is drawing attention as mental health is a huge unmet need ^[97].
• Challenges: Biotech remains inherently high-risk. Clinical trial failures can crush stock prices overnight. The regulatory environment adds uncertainty – while FDA has been approving record numbers of drugs, there’s always a risk of stricter regulations or drug pricing reforms. 2025 also faces some overhang from drug price negotiation rules (in the US) and patent cliffs for big pharma, which could indirectly affect biotech valuations if M&A slows. Additionally, financing is a challenge: after the 2021 boom, funding dried up, and 2024 had the lowest follow-on offerings since 2016 ^[98]. In 2025, only the strongest biotechs can tap capital markets on good terms, though VC funding stabilized around $5–7B per quarter ^[99].
• Outlook: Many analysts see selective opportunities for biotech outperformance in late 2025 and beyond, especially if the Fed eases policy. Morgan Stanley identified possible boosts including lower rates and a wave of innovation that could reignite investor interest ^[100]. However, the industry is likely to remain volatile and driven by catalysts (trial readouts, FDA decisions). Unlike Diginex’s ESG sector which is driven by broad mandates, biotech stocks will rise or fall largely on individual milestones.

In sum, biotech in 2025 is cautiously optimistic – the sector has underperformed for a couple years and could be turning a corner, but fundamental challenges persist. Interestingly, a parallel can be drawn between Diginex and an early-stage biotech: both have uncertain near-term earnings, rely on future breakthroughs (for Diginex, market adoption; for biotechs, drug approvals), and both can see outsized stock moves on news flow. Investors in DGNX should take lessons from biotech investing: diversify risk, be prepared for volatility, and focus on progress against milestones (in Diginex’s case: integration of acquisitions, client growth, etc.).

Conclusion

Diginex (DGNX) offers a compelling narrative at the crossroads of two timely trends: the rise of ESG/sustainable investing and the power of AI/data in business. In 2025, the company has leveraged this narrative to fuel an extraordinary stock rally and execute bold strategic moves. Diginex’s current position can be summarized as: richly valued, rapidly evolving, and aiming for market leadership in ESG tech.

For investors, the stock presents a high-reward but high-risk proposition. On one hand, Diginex could become an indispensable platform for thousands of companies navigating sustainability compliance – a lucrative niche if all goes well. Its partnerships and acquisitions have set the stage for explosive growth (the company posted 57% sales growth in 2025 and may accelerate if new deals contribute ^[101]). Moreover, big-name backers and global expansion hint at a long runway ahead.

On the other hand, the current $3 billion valuation leaves little room for error. Execution risks are significant: integrating large acquisitions like Resulticks, realizing revenue from its expanded product suite, and managing a much larger organization will be challenging for a firm of Diginex’s young age. Any sign of growth faltering or deals not panning out could trigger a sharp correction given the sky-high expectations embedded in the price (recall that the consensus rating is “Sell” for a reason ^[102]). Additionally, macro factors – e.g. if interest rates remain high or if there’s backlash against ESG – could dampen enthusiasm.

For the general public interested in biotech investing, Diginex’s story is a fascinating case study that extends beyond traditional biotech. It shows how markets reward “the next big thing,” be it a cure for a disease or a solution for sustainability reporting. The key is to balance the vision with vigilance: as with a promising drug candidate, one must track Diginex’s clinical milestones (in this case, business milestones). Upcoming checkpoints for DGNX will include closing the Resulticks acquisition, demonstrating revenue growth from these new businesses, and possibly uplisting in Abu Dhabi or another capital raise.

Bottom line: Diginex has positioned itself at the forefront of an emerging industry with enormous potential. The stock’s 2025 journey – from obscurity to a 35-fold increase – underscores both the excitement and risk inherent in early-stage growth companies. Investors should keep an eye on this ESG tech upstart, but approach it with the same caution and due diligence they would apply to any biotech moonshot. In a market that’s increasingly rewarding sustainability and innovation, Diginex is a company to watch – just remember that even the brightest growth stories can face rough patches on the road to maturity.

Sources: Diginex company filings and press releases; Yahoo Finance and Reuters market data ^{[103] [104]}; StockAnalysis and Macrotrends financial statistics ^{[105] [106]}; GlobeNewswire announcements (June 5, 2025; May 27, 2025; Aug 18, 2025) ^{[107] [108] [109]}; Insider Monkey and Seeking Alpha analysis pieces ^{[110] [111]}; MarketBeat and Directorstalk analyst commentary ^{[112] [113]}; industry outlook reports (Morgan Stanley, etc.) ^{[114] [115]}. All information is current as of October 2025.

References

1. www.reuters.com, 2. www.reuters.com, 3. www.reuters.com, 4. www.reuters.com, 5. www.reuters.com, 6. www.reuters.com, 7. www.reuters.com, 8. www.reuters.com, 9. www.marketbeat.com, 10. www.reuters.com, 11. www.reuters.com, 12. www.globenewswire.com, 13. www.globenewswire.com, 14. stockanalysis.com, 15. stockanalysis.com, 16. www.globenewswire.com, 17. www.globenewswire.com, 18. www.marketlog.com, 19. stockanalysis.com, 20. www.reuters.com, 21. www.reuters.com, 22. www.insidermonkey.com, 23. www.insidermonkey.com, 24. www.insidermonkey.com, 25. www.globenewswire.com, 26. www.globenewswire.com, 27. www.globenewswire.com, 28. www.globenewswire.com, 29. www.globenewswire.com, 30. www.globenewswire.com, 31. www.globenewswire.com, 32. www.insidermonkey.com, 33. www.globenewswire.com, 34. www.globenewswire.com, 35. www.globenewswire.com, 36. www.globenewswire.com, 37. www.globenewswire.com, 38. www.globenewswire.com, 39. www.globenewswire.com, 40. www.globenewswire.com, 41. www.globenewswire.com, 42. www.globenewswire.com, 43. stockanalysis.com, 44. stockanalysis.com, 45. stockanalysis.com, 46. stockanalysis.com, 47. stockanalysis.com, 48. stockanalysis.com, 49. www.marketbeat.com, 50. www.marketbeat.com, 51. www.marketbeat.com, 52. www.zacks.com, 53. www.marketbeat.com, 54. www.marketbeat.com, 55. www.marketlog.com, 56. www.insidermonkey.com, 57. www.insidermonkey.com, 58. www.marketbeat.com, 59. www.marketbeat.com, 60. coincodex.com, 61. www.marketbeat.com, 62. www.marketlog.com, 63. www.insidermonkey.com, 64. www.insidermonkey.com, 65. www.reuters.com, 66. www.directorstalkinterviews.com, 67. www.macrotrends.net, 68. www.macrotrends.net, 69. www.reuters.com, 70. companiesmarketcap.com, 71. stockanalysis.com, 72. www.reuters.com, 73. www.reuters.com, 74. www.insidermonkey.com, 75. www.globenewswire.com, 76. www.globenewswire.com, 77. investor.ghres.com, 78. www.directorstalkinterviews.com, 79. investors.beamtx.com, 80. www.reuters.com, 81. www.marketbeat.com, 82. www.directorstalkinterviews.com, 83. www.directorstalkinterviews.com, 84. www.directorstalkinterviews.com, 85. www.morganstanley.com, 86. finance.yahoo.com, 87. www.directorstalkinterviews.com, 88. www.directorstalkinterviews.com, 89. www.futunn.com, 90. www.globenewswire.com, 91. www.globenewswire.com, 92. stockanalysis.com, 93. www.futunn.com, 94. www.morganstanley.com, 95. biotechbreakthroughawards.com, 96. distance.physiology.med.ufl.edu, 97. www.directorstalkinterviews.com, 98. www.ey.com, 99. www.dcatvci.org, 100. www.morganstanley.com, 101. www.reuters.com, 102. www.marketbeat.com, 103. www.reuters.com, 104. www.reuters.com, 105. stockanalysis.com, 106. companiesmarketcap.com, 107. www.globenewswire.com, 108. www.globenewswire.com, 109. www.insidermonkey.com, 110. www.insidermonkey.com, 111. www.marketlog.com, 112. www.marketbeat.com, 113. www.directorstalkinterviews.com, 114. www.morganstanley.com, 115. www.futunn.com